Clinical care and other categories posters: Secondary care

Clinical care and other categories posters: Secondary care P477Experience with dulaglutide in a real‐world settingS ZOURAS1, JW Stephens1,2, DE Price1 and W Syed11Department of Diabetes & Endocrinology, Morriston Hospital, ABM University Health Board, Swansea, UK, 2Diabetes Research Group, University of Swansea, Swansea, UKAims: Dulaglutide is a once weekly administered glucagon‐like peptide (GLP)‐1 analogue, which is now available for use in the United Kingdom. We examined the clinical benefits of treatment with dulaglutide in a sample of secondary care patients attending our local diabetes clinic.Methods: All patients commenced on dulaglutide at Morriston Hospital are routinely monitored to assess the efficacy of the product. Glycaemic control, weight and the use of other concomitant therapies are recorded as part of their follow‐up. To date, 21 patients with Type 2 diabetes have been initiated on dulaglutide with six‐month follow‐up data available.Results: The mean age of the sample was 59 ± 13 years and comprised of 16 males and 5 females. Baseline weight and HbA1c were 115.0 ± 23.6 kg and 79.1 ± 4 mmol/mol respectively. At six months the respective values were 112.32 ± 5.5 kg (p = 0.007) and 70 ± 18 mmol/mol (p = 0.03). No statistical changes were observed for serum creatinine, eGFR, triglyceride and albumin:creatinine ratio. Of interest, a significant reduction was seen in total cholesterol from 4.4 ± 1.2 mmol/l to 4.1 ± 1.2 mmol/l (p = 0.01). Of note, four patients were http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Clinical care and other categories posters: Secondary care

Loading next page...
 
/lp/wiley/clinical-care-and-other-categories-posters-secondary-care-tdsLRP3A5a
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
D.O.I.
10.1111/dme.55_13571
Publisher site
See Article on Publisher Site

Abstract

P477Experience with dulaglutide in a real‐world settingS ZOURAS1, JW Stephens1,2, DE Price1 and W Syed11Department of Diabetes & Endocrinology, Morriston Hospital, ABM University Health Board, Swansea, UK, 2Diabetes Research Group, University of Swansea, Swansea, UKAims: Dulaglutide is a once weekly administered glucagon‐like peptide (GLP)‐1 analogue, which is now available for use in the United Kingdom. We examined the clinical benefits of treatment with dulaglutide in a sample of secondary care patients attending our local diabetes clinic.Methods: All patients commenced on dulaglutide at Morriston Hospital are routinely monitored to assess the efficacy of the product. Glycaemic control, weight and the use of other concomitant therapies are recorded as part of their follow‐up. To date, 21 patients with Type 2 diabetes have been initiated on dulaglutide with six‐month follow‐up data available.Results: The mean age of the sample was 59 ± 13 years and comprised of 16 males and 5 females. Baseline weight and HbA1c were 115.0 ± 23.6 kg and 79.1 ± 4 mmol/mol respectively. At six months the respective values were 112.32 ± 5.5 kg (p = 0.007) and 70 ± 18 mmol/mol (p = 0.03). No statistical changes were observed for serum creatinine, eGFR, triglyceride and albumin:creatinine ratio. Of interest, a significant reduction was seen in total cholesterol from 4.4 ± 1.2 mmol/l to 4.1 ± 1.2 mmol/l (p = 0.01). Of note, four patients were

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial